Erasca, Inc. (ERAS) · Nov 20, 2026 · Other events

Erasca clinical data advances Phase 3 timing as responses hold

Phase 3 accelerated — 1L PDAC Phase 3 moved to 1H27; 44% confirmed ORR in 2L+ PDAC

Erasca’s latest clinical-data update shows confirmed activity for ERAS-0015 across pancreatic and lung cancers, while accelerating its pancreatic Phase 3 timeline.

Erasca is a clinical-stage precision-oncology company building ERAS-0015 into a potential backbone therapy across RAS-mutant cancers, with multiple pivotal-path studies already planned and substantial funding to execute them.

The main change is stronger-than-routine clinical validation. In heavily pretreated KRAS-mutant pancreatic cancer, ERAS-0015 produced a 44% confirmed response rate across 25 patients at 32 mg, including 69% in the narrower G12D/G12V subgroup; the lung-cancer signal was also 58% across the active-dose range. Those are small, uncontrolled Phase 1 cohorts, but confirmed responses and continued treatment among responders make the data more durable than an early unconfirmed signal.

MeasureCurrent dataComparator
PDAC confirmed ORR, KRAS G12X (Financial Highlights)44%N=25
PDAC confirmed ORR, KRAS G12D/V (Financial Highlights)69%N=13
NSCLC confirmed ORR, 16–32 mg (Financial Highlights)58%N=12
TRAE dose discontinuations, 32 mg (Safety Data)0%2L+ safety set

The timeline moved forward, not merely sideways. Before this update, Erasca had already telegraphed a 2027 first-line pancreatic Phase 3, so the existence of the trial is not new. The filing makes the timing more specific—first half of 2027—and ties that acceleration to the updated response data. That is a modest upgrade to execution confidence, not a wholesale rewrite of the development story.

The evidence still stops short of proving a registrational-quality advantage. The combination cohorts have not yet produced efficacy data in the gemcitabine/nab-paclitaxel arm, the patient counts remain small, and the filing retains a prior fatal pneumonitis event in its safety discussion. The 4001 combination thesis is also still mostly preliminary and nonclinical, so it adds optionality rather than validated value. 〔0〕 〔1〕

Bottom line: This advances Erasca’s story because the key ERAS-0015 responses are now confirmed across pancreatic and lung cancers and management is moving the pivotal pancreatic trial into the first half of 2027. It is a meaningful but still incremental positive, since the cohorts are early-stage and the broader combination thesis remains unproven.

What to watch next

ERAS-0015 Phase 3 PDAC trial initiation, first half 2027

Original filing on SEC EDGAR

More Erasca, Inc. news

Erasca clinical data advances Phase 3 timing as responses hold | ERAS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.